{"id":52464,"date":"2023-01-03T13:03:39","date_gmt":"2023-01-03T12:03:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/"},"modified":"2023-01-03T13:03:39","modified_gmt":"2023-01-03T12:03:39","slug":"allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"
\n

WALTHAM, Mass.–(BUSINESS WIRE)–AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023, at 2:15 p.m. PST.\n<\/p>\n

<\/a><\/p>\n

\nA live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at https:\/\/ir.allovir.com<\/a>.\n<\/p>\n

\nAbout AlloVir<\/b>\n<\/p>\n

\nAlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company\u2019s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir\u2019s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit www.allovir.com<\/a> or follow us on Twitter<\/a> or LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia and Investors:<\/b>
Sonia Choi
\n
AlloVir
\n
schoi@allovir.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass.–(BUSINESS WIRE)–AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023, at 2:15 p.m. PST. A live webcast and archived replay of the presentation will be … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52464","6":"format-standard","7":"category-industry"},"yoast_head":"\nAlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass.–(BUSINESS WIRE)–AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023, at 2:15 p.m. PST. A live webcast and archived replay of the presentation will be ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-03T12:03:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230103005155\/en\/1559742\/21\/AlloVir_Logo_FullColor%5B2%5D.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2023-01-03T12:03:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":214,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005155\\\/en\\\/1559742\\\/21\\\/AlloVir_Logo_FullColor%5B2%5D.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005155\\\/en\\\/1559742\\\/21\\\/AlloVir_Logo_FullColor%5B2%5D.jpg\",\"datePublished\":\"2023-01-03T12:03:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005155\\\/en\\\/1559742\\\/21\\\/AlloVir_Logo_FullColor%5B2%5D.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005155\\\/en\\\/1559742\\\/21\\\/AlloVir_Logo_FullColor%5B2%5D.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend","og_description":"WALTHAM, Mass.–(BUSINESS WIRE)–AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023, at 2:15 p.m. PST. A live webcast and archived replay of the presentation will be ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-03T12:03:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230103005155\/en\/1559742\/21\/AlloVir_Logo_FullColor%5B2%5D.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference","datePublished":"2023-01-03T12:03:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/"},"wordCount":214,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230103005155\/en\/1559742\/21\/AlloVir_Logo_FullColor%5B2%5D.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/","name":"AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230103005155\/en\/1559742\/21\/AlloVir_Logo_FullColor%5B2%5D.jpg","datePublished":"2023-01-03T12:03:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230103005155\/en\/1559742\/21\/AlloVir_Logo_FullColor%5B2%5D.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230103005155\/en\/1559742\/21\/AlloVir_Logo_FullColor%5B2%5D.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/allovir-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52464"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52464\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}